• Home
  • CML Experts
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • Other CML experts in America >
      • Other CML experts in Canada >
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connies Eaves
        • Dr. Josée Hébert
        • Dr. Pierre Laneuville
        • Dr. Jeffrey H Lipton
        • Dr. Luigina Mollica
      • Other CML experts in US >
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Rey Garcia, RN, BSN
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Arul Chinnaiyan
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Frank Giles
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Karen Seiter
        • Dr. Neil Shah
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Bin Zhang
    • Other CML Experts in Europe >
      • Dr. Jane Apperley
      • Dr. Michele Baccarani
      • Pr. Agnès Buzyn
      • Dr. Gabriel Etienne
      • Dr. Marie-Joëlle Mozziconacci
      • Dr. François Guilhot
      • Dr. Eliane Gluckman
      • Dr. Andreas Hochhaus
      • Dr. Stephen O'Brien
      • Stéphane Prost
      • Dr. Tessa L Holyoake
      • Dr. Hana Klamova
      • Dr. Jeroen J.W.M. Janssen
      • Dr. Franck-Emmanuel Nicolini
      • Dr. Delphine Rea
      • Dr. Johan Richter
      • Dr. Philippe Rousselot
      • Dr. Giuseppe Saglio
      • Dr. François-Xavier Mahon
      • Pr Gregor Verhoef
    • Other CML experts in Asia >
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • Other CML experts in Africa >
      • Dr. Anthony Oyekunle
    • Other CML experts in Australia >
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • Introduction to CML
    • Blood
    • Bone Marrow
    • DNA
    • Immune System >
      • Natural killer cell - NK
      • T Cells
    • JAK2 Gene
    • Treatment response in CML
    • Polymerase Chain Reaction
    • Stem Cells
    • Donor lymphocyte infusion (DLI)
    • Blood-Brain Barrier
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Gleevec (Imatinib)
    • Tasigna (Nilotinib)
    • Sprycel (Dasatinib)
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • Synribo (Omacetaxine )
    • (Bafetinib)
    • Jakafi (Ruxolitinib)
    • (Danusertib)
    • (Rebastinib)
    • BGB324
    • ABL001
    • PF-114
    • NEV-801
    • BP1001
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Heart
      • Hair
      • Kidney
      • Muscle cramping
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Skin
      • Weight gain
    • CML and Nutrition
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Music therapy >
        • YouTube creation by CMLer's family
        • Magnificent (I Believe)
        • Adagio for Strings (Samuel Barber)
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • Virginia Garner
    • Pat Elliott
    • Jan Geissler
    • Kris
    • Nigel
    • Katie
    • Tamera Simonson
    • Hans Loland
    • Erin Havel (Author)
    • Erin Zammett Ruddy
    • Rob Shick
    • Gary Gonzales
    • Ron Robbecke
    • Drew Johnston
    • Angela Tyrrell
    • Doug Jenson
    • Rich Jones
    • Kevin Williams
    • Jean McGlynn
    • Austin Granatowicz
    • Tom Cleaver
    • Others testimonials
    • Some celebrities >
      • Alexa Score
      • Laura Boyd
      • Dr. Richard Rockefeller
      • Tim Holcomb
      • Doris Muramatsu
      • Ryan O'Neal
      • Kelvin Alston
      • Kareem Abdul-Jabar
      • Jason Blake
      • Brian Boyle
      • Rick Upchurch
    • Bud Romine - the first patient
    • Kayla Naton (Pregnancy)
    • Suzan Mc Namara and the petition
  • Blogs
    • Access CML Drugs
    • Trey's CML Leukemia Blog
    • Living with CML
    • CMKID's blog – Dislodging the bullet
    • CML Recovery - Stopping KTI
    • Hans's Blog
    • Elizabeth's Blog - my leukemia journey
    • Elizabeth's Blog - Heart of the rose
    • Ian's Blog
    • Joe's Blog
    • Jon's Blog
    • Josh's Blog
    • Mannan's Blog
    • Justin Ozuna's Blog
    • Lindsey's Blog
    • Matt's Blog
    • Matthew's Blog
    • Michelle's Blog
    • Michelle D's Blog
    • Nayree's Blog
    • Rob's Blog
  • News on CML (Chronic myeloid leukemia)
    • English >
      • English - Archives 2015-2001
    • French (Français)
    • Spanish (Español)
  • Various topics
    • You’ve just been diagnosed
    • History of CML
    • Cure possible for CML? >
      • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
      • Inhibition of the protein Ezh2 can cure CML?
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Inhibition of STAT5 in conjunction with standard TKI therapy
      • CML vaccine
      • Can immunotherapy cure leukemia?
      • Chimeric Antigen Receptor T-Cell Therapy
      • Can genetic sequencing help to cure leukemia?
      • Natural Medicine >
        • Possible cure for CML in Fish Oil
        • Betel leaf may help fight CML
        • Feverfew extract (parthenolide)
        • Can dandelions kill cancer?
        • Can curcumin cure leukemia?
      • Can the new drug CX-5461 cure leukemia?
      • CRISPR-Cas9 gene-editing technique
      • Presence of bcr abl fusion transcripts in healthy individua
      • Math could help cure leukemia
    • Treatment free remission (TFR ) >
      • The French trial called STIM (Stop Imatinib)
    • CML causes
    • CML and pregnancy
    • Children with CML
    • Food and Drug Interactions
    • Bone marrow transplant
    • CML Blast Crisis treatment
    • Stem cells from umbilical cord blood
    • Mutation T315I
    • Sensitive detection of BCR-ABL1 mutations
    • Elderly patients with CML
    • Living with CML and diabetes
    • Non-adherence of CML patients
    • Sports with CML
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • CML Awareness Day
  • Congresses, conferences, meetings ASH, ASCO, EHA ...
    • ASCO - American Society of Clinical Oncology >
      • ASCO 2017 - Chicago
      • ASCO 2016 - Chicago
      • ASCO 2015 - Chicago
      • ASCO 2014 - Chicago
      • ASCO 2013 - Chicago
      • ASCO 2012 - Chicago
      • ASCO 2011 - Chicago
      • ASCO 2010 - Chicago
    • ASH - American Society of Hematology >
      • ASH 2017 - Atlanta
      • ASH 2016 - San Diego
      • ASH 2015 - Orlando
      • ASH 2014 - San Francisco
      • ASH 2013 - New Orleans
      • ASH 2012 - Atlanta
      • ASH 2011 - San Diego
      • ASH 2010 - Orlando
      • ASH 2009 - New Orleans
    • BTG - Bridging the Gap >
      • BTG 2011 - Singapore (Singapore)
    • CML & MPDs - UK National Meetings
    • CML Horizons >
      • CML Horizon 2016 - Ljubljana (Slovenia)
      • CML Horizons 2015 - (Barcelona, Spain)
      • CML Horizons 2014 - ( Belgrade, Serbia)
      • CML Horizons 2013 - (Prague - Czech Republic)
      • CML Horizons 2012 - (Munich, Germany)
      • CML Horizons 2011 - (Amsterdam - The Netherlands)
    • EHA - European Hematology Association >
      • ESH - European School of Haematology >
        • ESH 2016 - Houston - USA
        • ESH 2015 - Estoril - Portugal
        • ESH 2014 - Philadelphia
      • EHA 2017 - Madrid (Spain)
      • EHA2016-Copenhagen,(Denmark)
      • EHA 2015 - Vienne (Austria)
      • EHA 2014 - Milan (Italy)
      • EHA 2013 - Stockholm (Sweden)
      • EHA 2012 - Amsterdam (The Netherlands)
      • EHA 2011 - London (England)
      • EHA 2010 - Cascais (Portugal)
      • EHA 2009 - Berlin (Germany)
      • EHA 2008 - Copenhague (Danemark)
  • Educational videos
    • Educational videos (in English)
    • Educación de vídeos en español (in Spanish)
    • Vidéos pédagogiques en français (in French)
  • Educational events
  • CML Glossaries
  • Professionnel help and literature
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Patient Rights
  • Moral Support
    • Where to get help and support
    • Family support
    • I Had Cancer: You are not alone
    • The march toward healing
    • Be happy
    • Dances at the Cancer Research Centre
    • The spoon theory
    • Stronger
    • Magnificent - Beauty of nature
  • Links to other sites, forums and Facebook
    • Sites ( English and other languages)
    • Forums
    • CML on Facebook
    • CML on Twitter
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
      • Audio Podcast
    • Hospital Foundations
  • Contact us
  • About us
Chronic Myeloid Leukemia

ASH 2015 - Orlando - CML - Chronic  Myeloid Leukemia

2015 ASH 57th ASH Annual Meeting and Exposition (December 5-8, 2015)
    
CML Program

Saturday, December 5, 2015
Managing Typical and Atypical Chronic Myeloid Leukemia 
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: CML – Mechanisms of Disease Progression and Leukemic Stem Cell Persistence
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I  
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia  
632. Chronic Myeloid Leukemia: Therapy: Poster I  
632. Chronic Myeloid Leukemia: Therapy Program: Oral and Poster Abstracts  Type: Poster
632. Chronic Myeloid Leukemia: Therapy: Clinical Trials, Observations, and Molecular Monitoring

Sunday, December 6, 2015
632. Chronic Myeloid Leukemia: Therapy: Treatment-Free Remission, Mutations, and Prognosis  
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II  
632. Chronic Myeloid Leukemia: Therapy: Poster II  

Monday, December 7, 2015
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III  
632. Chronic Myeloid Leukemia: Therapy: Poster III  
632. Chronic Myeloid Leukemia: Therapy: Clinical and Molecular Predictors of Outcomes and Toxicities  
632. Chronic Myeloid Leukemia: Therapy and Prognosis  

Forums and Patient associations 'reports

iCMLf Forum during ASH on December 4, 2015:Case discussions on CML management for physicians from Emerging Economic Regions
 
Abstracts and notes on CML presentations  at ASH 2015. Orlando
By  Steve O’Brien, Newcastle University

NEWS

First-line dasatinib plus pegylated-interferon alpha 2b induces deep molecular responses in CML
December 7, 2015, Healio

In CP-CML, Deep Molecular Responses to TKIs Result from Immune Suppressor Activity
December 5, 2015,  OncologyNurseAdvisor

VIDEO

CML Takeaways From ASH 2015: Discontinuing Tyrosine Kinase Inhibitors
December 22, 2015, Medscape Oncology

SOME INTERESTING ABSTRACTS FOR CML


Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance

Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study
 
Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Inecalcitol, a Novel Adjuvant Therapy Inhibiting Chronic Myeloid Leukemia (CML) Stem Cells,  Activates a Macrophage Differentiation Pathway in Leukemic Progenitors

The Long Non-Coding RNA NEAT1 Modulates Imatinib-Induced Apoptosis in CML Cells

Pulmonary Complications in Patients Treated with Tyrosine Kinase Inhibitors, a Systematic Review and Meta-Analysis

Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias

Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan

Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?

Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study

Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study

Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Velocity of Early BCR-ABL Transcript Elimination As an Optimized Predictor of Deep Molecular Response in Chronic Myeloid Leukemia Patients in Chronic Phase on Treatment with Dasatinib

Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib

Interim Analysis of a Multicenter, Prospective Study for Pediatric Chronic Myeloid Leukemia in Chronic Phase: The JPLSG CML-08 Study

Description and Management of Accelerated Phase and Blast Crisis in 21 CML Pediatric Patients

          (See our disclaimer - Voir notre avis de non-responsabilité- Vea nuestro aviso legal).

Copyright © 2010-2018 CMLeukemia.com
DMCA.com Protection Status
✕